[1] LIN Xinjing ZHANG Ming LI Xin ZHOU Chunyang PU Yue YUAN Bin FAN Yibin FAN Runyong XIA Tianqin YOU Jun YANG Xiaoxi,.Experimental Study on Acute Toxicity of Tiaozang Shubi Mixture in Mice [J]. Modern Traditional Chinese Medicine, 2023, (02): 91-95. [doi: 10.13424/j.cnki.mtcm.2023.02.019]
Experimental Study on Acute Toxicity of Tiaozang Shubi Mixture in Mice
- Article number:
- 1672-0571(2023)02-0091-05
- Keywords:
- Key words:Tiaozang Shubi Mixture; Gavage; Acute toxicity; Mice; Liver function; Renal function
- ZTFLH:
- R285.5
- Code:
- A
- Abstract:
- Objective To explore the acute toxicity of Tiaozang Shubi mixture in mice after oral administration.Methods Kunming mice were randomly divided into control group,normal group and maximum group.The drug was administered by gavage at the dose of 20.8 g·kg-1 and 104 g·kg-1 respectively.Repeat administration twice within 24 hours.The changes of body weight,mental state,activity,diet and excretion of mice were observed and recorded within 14 days.Elisa was used to detect the liver function indicators of glutamic-pyruvic transaminase(ALT) and glutamic-oxalacetic transaminase(AST),and the renal function indicators of blood urea nitrogen(BUN) and creatinine(CRE).HE staining was used to observe the pathological changes of liver,kidney,spleen and colon in mice.Results Compared with the control group,the body weight of mice in the normal group and the maximum group did not change significantly,and their appearance,mental state,diet,excreta and general conditions were normal.No obvious changes were found in the liver,kidney,colon and spleen of the mice by anatomical and macroscopic observation,and no obvious pathological changes were found in the tissues by HE staining.Compared with the control group,the liver function and kidney function of the normal group and the maximum group had no significant changes.Conclusion Tiaozang Shubi Mixture did not cause toxic damage in mice at the maximum dose of 104 g·kg-1.
References:
[1]刘启鸿,柯晓,骆云丰,等.理气通便方治疗慢传输型便秘气滞证30例随机对照试验[J].中医杂志,2021,62(7):604-608.
[2]王澍彬,徐小玲,周义,等.大黄配方颗粒对慢性传输性便秘模型大鼠Cajal间质细胞自噬及胃肠动力调节作用研究[J].国际中医中药杂志,2021,43(8):777-783.
[3]牛媛媛,汪龙德,胥文娟,等.汪龙德主任医师辨证论治功能性便秘经验[J].陕西中医药大学学报,2022,45(5):30-34.
[4]赵向东,曹永清,徐向.基于中医传承辅助系统的曹永清治疗便秘用药规律研究[J].国际中医中药杂志,2020,42(6):583-587.
[5]王芳.中医治疗便秘的研究进展[J].临床合理用药杂志,2020,13(1):171-173.
[6]黎琮毅.功能性便秘的中医治疗研究进展[J].实用中医内科杂志,2020,34(4):20-24.
[7]王微微,范红结,杨文红,等.金钗石斛提取物对便秘模型小鼠通便功能的影响[J].食品工业科技,2021,42(20):342-347.
[8]范艺缤,魏照洲,唐学贵,等.调脏舒秘汤加减治疗慢传输型便秘临证探析[J].实用中医药杂志,2019,35(6):749-750.
[9]范艺缤,吴至久,魏照洲.调脏舒秘汤对慢传输型便秘大鼠结肠推进率和微管相关蛋白2表达影响的实验研究[J].中医药临床杂志,2016,28(9):1263-1266.
[10]夏青,张晓昕,徐柯心,等.《中华人民共和国药典》2015版收载的有毒中药毒性研究概况[J].环球中医药,2017,10(3):377-384.
[11]朱凤,刘与进,吴慧,等.医院制剂复方苦参合剂对小鼠急性毒性实验研究[J].亚太传统医药,2021,17(1):22-24.
[12]《中药、天然药物急性毒性试验技术指导原则》课题研究组.中药、天然药物急性毒性研究技术指导原则
[S
].GPT2-1,2004．
[13]宋瑞芳.《内经》关于便秘的认识[J].现代中医药,2021,41(1):106-110.
[14]胡绍杰,蒋莎莎,张瑾,等.细胞凋亡在肝脏衰老中的作用[J].生命科学研究,2018,22(5):397-405.
[15]师少军.肝脏“代谢-转运互作”及其对药物药代动力学、疗效和毒性影响的研究进展[J].中国医院药学杂志,2020,40(5):579-585.
[16]刘程程,张嘉阳,杨光锐,等.生物钟基因与肾脏功能和疾病[J].生命科学,2021,33(6):736-741.
[17]林志,李珊珊,张頔,等.药物临床前安全性评价中脾脏的作用和意义[J].医学研究杂志,2010,39(1):111-113.
[18]田海军,刘开放,任胜杰.十二烷基苯磺酸钠对黄河鲤急性毒性及血液生理生化指标的影响[J].水产科学,2021,40(3):380-386.
[19]吴倩.血清胱抑素C、肌酐、尿素氮联合检测在肾功能损害诊断中的应用价值[J].临床医学,2022,42(10):68-69.
[20]杨琳,高淑婷,许欢.温肾健脾利水方联合缬沙坦胶囊治疗脾肾气虚型慢性肾小球肾炎临床研究[J].新中医,2022,54(23):93-97.
[21]许丽,孙祖越.常见实验动物血液学和血清生化指标背景数据的建立
[C
]//中国毒理学会第四届中青年学者科技论坛论文集,2014:41.
[22]唐炯,陆春梅.百令胶囊联合肾衰宁颗粒治疗慢性肾功能衰竭的疗效观察[J].世界中西医结合杂志,2022,17(10):2029-2034.
[23]董书清.血清肌酐、尿素氮的检测值及其比值与肾脏损害的探讨[J].中国医药指南,2011,9(36):136-137.
[24]聂青和.肝衰竭实验室检测的临床价值及新指标评价[J].临床肝胆病杂志,2013,29(9):666-669.
[25]蒋平,杨阳,孙阳,等.养胃颗粒灌胃给药对小鼠的急性毒性实验[J].时珍国医国药,2014,25(4):841-843.
[26]谢秀琼.中药新制剂开发与应用[M].3版.北京:人民卫生出版社,2006:726-747.
Memo
基金项目：四川省科技计划项目-重点研发项目（2020YFS0528)